Shares of Xencor Inc (NASDAQ:XNCR) have received a consensus recommendation of “Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $47.88.

A number of analysts recently commented on the company. Zacks Investment Research raised Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, July 20th. Guggenheim lowered Xencor from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Wedbush raised their price target on Xencor from $43.00 to $54.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. They noted that the move was a valuation call. Piper Jaffray Companies raised their price target on Xencor from $56.00 to $67.00 and gave the stock an “overweight” rating in a research note on Monday, July 8th. Finally, ValuEngine raised Xencor from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd.

XNCR stock traded down $0.10 on Friday, reaching $35.38. The company’s stock had a trading volume of 251,194 shares, compared to its average volume of 314,301. The business has a fifty day simple moving average of $39.29 and a two-hundred day simple moving average of $35.45. Xencor has a 12-month low of $27.75 and a 12-month high of $48.38. The firm has a market cap of $2.01 billion, a PE ratio of -27.01 and a beta of 1.44. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.27 and a current ratio of 8.27.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Xencor had a return on equity of 8.40% and a net margin of 28.46%. The company had revenue of $19.49 million during the quarter, compared to analyst estimates of $7.58 million. As a group, research analysts anticipate that Xencor will post 0.05 earnings per share for the current fiscal year.

In other Xencor news, VP John R. Desjarlais sold 35,000 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $40.69, for a total value of $1,424,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John J. Kuch sold 40,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $41.27, for a total value of $1,650,800.00. The disclosure for this sale can be found here. 4.33% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of XNCR. Quantamental Technologies LLC bought a new position in Xencor in the second quarter worth $76,000. Royal Bank of Canada raised its holdings in Xencor by 42.7% in the second quarter. Royal Bank of Canada now owns 2,004 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 600 shares in the last quarter. Shell Asset Management Co. bought a new position in Xencor in the first quarter worth $145,000. Aperio Group LLC bought a new position in Xencor in the second quarter worth $152,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Xencor by 42.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,911 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 1,160 shares in the last quarter. Institutional investors and hedge funds own 84.00% of the company’s stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Read More: What is the Russell 2000 Index?

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.